RESUMEN
CDK7 associates with the 10-subunit TFIIH complex and regulates transcription by phosphorylating the C-terminal domain (CTD) of RNA polymerase II (RNAPII). Few additional CDK7 substrates are known. Here, using the covalent inhibitor SY-351 and quantitative phosphoproteomics, we identified CDK7 kinase substrates in human cells. Among hundreds of high-confidence targets, the vast majority are unique to CDK7 (i.e., distinct from other transcription-associated kinases), with a subset that suggest novel cellular functions. Transcription-associated factors were predominant CDK7 substrates, including SF3B1, U2AF2, and other splicing components. Accordingly, widespread and diverse splicing defects, such as alternative exon inclusion and intron retention, were characterized in CDK7-inhibited cells. Combined with biochemical assays, we establish that CDK7 directly activates other transcription-associated kinases CDK9, CDK12, and CDK13, invoking a "master regulator" role in transcription. We further demonstrate that TFIIH restricts CDK7 kinase function to the RNAPII CTD, whereas other substrates (e.g., SPT5 and SF3B1) are phosphorylated by the three-subunit CDK-activating kinase (CAK; CCNH, MAT1, and CDK7). These results suggest new models for CDK7 function in transcription and implicate CAK dissociation from TFIIH as essential for kinase activation. This straightforward regulatory strategy ensures CDK7 activation is spatially and temporally linked to transcription, and may apply toward other transcription-associated kinases.
Asunto(s)
Quinasas Ciclina-Dependientes/metabolismo , Modelos Biológicos , Factor de Transcripción TFIIH/metabolismo , Transcripción Genética/genética , Empalme Alternativo/genética , Supervivencia Celular/efectos de los fármacos , Quinasas Ciclina-Dependientes/antagonistas & inhibidores , Quinasas Ciclina-Dependientes/genética , Activación Enzimática/genética , Células HL-60 , Humanos , Quinasa Activadora de Quinasas Ciclina-DependientesRESUMEN
Although optimizing the resistance profile of an inhibitor can be challenging, it is potentially important for improving the long term effectiveness of antiviral therapy. This work describes our rational approach toward the identification of a macrocyclic acylsulfonamide that is a potent inhibitor of the NS3-NS4A proteases of all hepatitis C virus genotypes and of a panel of genotype 1-resistant variants. The enhanced potency of this compound versus variants D168V and R155K facilitated x-ray determination of the inhibitor-variant complexes. In turn, these structural studies revealed a complex molecular basis of resistance and rationalized how such compounds are able to circumvent these mechanisms.
Asunto(s)
Proteínas Portadoras/química , Farmacorresistencia Viral , Hepatitis C/tratamiento farmacológico , Proteínas no Estructurales Virales/química , Antivirales/farmacología , Línea Celular , Clonación Molecular , Cristalografía por Rayos X/métodos , Genotipo , Humanos , Péptidos y Proteínas de Señalización Intracelular , Modelos Químicos , Modelos Moleculares , Conformación Molecular , Inhibidores de Proteasas/farmacología , Sulfonamidas/química , Rayos XRESUMEN
Phosphatidylinositol-4-kinase IIIα (PI4KIIIα) is an essential host cell factor for hepatitis C virus (HCV) replication. An N-terminally truncated 130-kDa form was used to reconstitute an in vitro biochemical lipid kinase assay that was optimized for small-molecule compound screening and identified potent and specific inhibitors. Cell culture studies with PI4KIIIα inhibitors demonstrated that the kinase activity was essential for HCV RNA replication. Two PI4KIIIα inhibitors were used to select cell lines harboring HCV replicon mutants with a 20-fold loss in sensitivity to the compounds. Reverse genetic mapping isolated an NS4B-NS5A segment that rescued HCV RNA replication in PIK4IIIα-deficient cells. HCV RNA replication occurs on specialized membranous webs, and this study with PIK4IIIα inhibitor-resistant mutants provides a genetic link between NS4B/NS5A functions and PI4-phosphate lipid metabolism. A comprehensive assessment of PI4KIIIα as a drug target included its evaluation for pharmacologic intervention in vivo through conditional transgenic murine lines that mimic target-specific inhibition in adult mice. Homozygotes that induce a knockout of the kinase domain or knock in a single amino acid substitution, kinase-defective PI4KIIIα, displayed a lethal phenotype with a fairly widespread mucosal epithelial degeneration of the gastrointestinal tract. This essential host physiologic role raises doubt about the pursuit of PI4KIIIα inhibitors for treatment of chronic HCV infection.
Asunto(s)
1-Fosfatidilinositol 4-Quinasa/metabolismo , Hepacivirus/fisiología , Interacciones Huésped-Patógeno , Replicación Viral , 1-Fosfatidilinositol 4-Quinasa/antagonistas & inhibidores , Animales , Antivirales/farmacología , Línea Celular , Análisis Mutacional de ADN , Farmacorresistencia Viral , Inhibidores Enzimáticos/farmacología , Femenino , Genes Esenciales , Hepatocitos/enzimología , Hepatocitos/virología , Humanos , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Ratones Transgénicos , Proteínas Mutantes/genética , Proteínas no Estructurales Virales/genéticaRESUMEN
A number of potent peptidic inhibitors of the NS3 protease have been described in the literature based on a substrate-based approach. In an on-going effort to reduce the peptidic character of this class of inhibitors, two novel series of analogs have been prepared in which the usual P3 amino acid residue is replaced by a succinamide fragment. This new backbone modification not only reduces the peptidic nature of traditional inhibitors but also provides new SAR opportunities for the capping group. Optimization of each of these two series resulted in inhibitors with sub-nanomolar potencies.
Asunto(s)
Amidas/química , Hepacivirus/enzimología , Inhibidores de Proteasas/química , Succinatos/química , Proteínas no Estructurales Virales/antagonistas & inhibidores , Amidas/farmacocinética , Animales , Perros , Semivida , Haplorrinos , Humanos , Microsomas Hepáticos/metabolismo , Modelos Moleculares , Inhibidores de Proteasas/farmacocinética , Ratas , Relación Estructura-Actividad , Succinatos/farmacocinética , Proteínas no Estructurales Virales/metabolismoRESUMEN
In this report we describe the synthesis and evaluation of diverse 4-arylproline analogs as HCV NS3 protease inhibitors. Introduction of this novel P2 moiety opened up new SAR and, in combination with a synthetic approach providing a versatile handle, allowed for efficient exploitation of this novel series of NS3 protease inhibitors. Multiple structural modifications of the aryl group at the 4-proline, guided by structural analysis, led to the identification of analogs which were very potent in both enzymatic and cell based assays. The impact of this systematic SAR on different drug properties is reported.
Asunto(s)
Antivirales/síntesis química , Hepacivirus/enzimología , Prolina/análogos & derivados , Inhibidores de Proteasas/síntesis química , Proteínas no Estructurales Virales/antagonistas & inhibidores , Animales , Antivirales/química , Antivirales/farmacocinética , Sitios de Unión , Diseño de Fármacos , Semivida , Hepacivirus/fisiología , Simulación del Acoplamiento Molecular , Prolina/síntesis química , Prolina/farmacocinética , Inhibidores de Proteasas/química , Inhibidores de Proteasas/farmacocinética , Estructura Terciaria de Proteína , Ratas , Relación Estructura-Actividad , Proteínas no Estructurales Virales/metabolismo , Replicación Viral/efectos de los fármacosRESUMEN
Hepatitis C virus infection, a major cause of liver disease worldwide, is curable, but currently approved therapies have suboptimal efficacy. Supplementing these therapies with direct-acting antiviral agents has the potential to considerably improve treatment prospects for hepatitis C virus-infected patients. The critical role played by the viral NS3 protease makes it an attractive target, and despite its shallow, solvent-exposed active site, several potent NS3 protease inhibitors are currently in the clinic. BI 201335, which is progressing through Phase IIb trials, contains a unique C-terminal carboxylic acid that binds noncovalently to the active site and a bromo-quinoline substitution on its proline residue that provides significant potency. In this work we have used stopped flow kinetics, x-ray crystallography, and NMR to characterize these distinctive features. Key findings include: slow association and dissociation rates within a single-step binding mechanism; the critical involvement of water molecules in acid binding; and protein side chain rearrangements, a bromine-oxygen halogen bond, and profound pK(a) changes within the catalytic triad associated with binding of the bromo-quinoline moiety.
Asunto(s)
Proteínas Portadoras/antagonistas & inhibidores , Proteínas Portadoras/química , Hepacivirus/enzimología , Oligopéptidos/química , Inhibidores de Proteasas/química , Tiazoles/química , Proteínas no Estructurales Virales/antagonistas & inhibidores , Proteínas no Estructurales Virales/química , Ácidos Aminoisobutíricos , Dominio Catalítico , Ensayos Clínicos Fase I como Asunto , Cristalografía por Rayos X , Hepatitis C/tratamiento farmacológico , Hepatitis C/enzimología , Humanos , Péptidos y Proteínas de Señalización Intracelular , Leucina/análogos & derivados , Resonancia Magnética Nuclear Biomolecular , Oligopéptidos/uso terapéutico , Prolina/análogos & derivados , Inhibidores de Proteasas/uso terapéutico , Unión Proteica , Quinolinas , Tiazoles/uso terapéuticoRESUMEN
The in vitro resistance profile of BI 201335 was evaluated through selection and characterization of variants in genotype 1a (GT 1a) and genotype 1b (GT 1b) replicons. NS3 R155K and D168V were the most frequently observed resistant variants. Phenotypic characterization of the mutants revealed shifts in sensitivity specific to BI 201335 that did not alter susceptibility to alpha interferon. In contrast to macrocyclic and covalent protease inhibitors, changes at V36, T54, F43, and Q80 did not confer resistance to BI 201335.
Asunto(s)
Hepacivirus/genética , Interferón-alfa/farmacología , Oligopéptidos/farmacología , Tiazoles/farmacología , Proteínas no Estructurales Virales/genética , Sustitución de Aminoácidos , Ácidos Aminoisobutíricos , Antivirales/farmacología , Cristalografía por Rayos X , Farmacorresistencia Viral , Genotipo , Hepacivirus/efectos de los fármacos , Hepacivirus/enzimología , Hepatitis C Crónica/tratamiento farmacológico , Hepatitis C Crónica/virología , Humanos , Concentración 50 Inhibidora , Cinética , Leucina/análogos & derivados , Mutagénesis Sitio-Dirigida , Tasa de Mutación , Fenotipo , Prolina/análogos & derivados , Inhibidores de Proteasas/farmacología , Quinolinas , Replicón , Proteínas no Estructurales Virales/metabolismoRESUMEN
Pharmacokinetic-pharmacodynamic (PK-PD) data analyses from early hepatitis C virus (HCV) clinical trials failed to show a good correlation between the plasma inhibitory quotient (IQ) and antiviral activity of different classes of directly acting antiviral agents (DAAs). The present study explored whether use of the liver partition coefficient-corrected IQ (LCIQ) could improve the PK-PD relationship. Animal liver partition coefficients (Kp(liver)) were calculated from liver to plasma exposure ratios. In vitro hepatocyte partition coefficients (Kp(hep)) were determined by the ratio of cellular to medium drug concentrations. Human Kp(liver) was predicted using an in vitro-in vivo proportionality method: the species-averaged animal Kp(liver) multiplied by the ratio of human Kp(hep) over those in animals. LCIQ was calculated using the IQ multiplied by the predicted human Kp(liver). Our results demonstrated that the in vitro-in vivo proportionality approach provided the best human Kp(liver) prediction, with prediction errors of <45% for all 5 benchmark drugs evaluated (doxorubicin, verapamil, digoxin, quinidine, and imipramine). Plasma IQ values correlated poorly (r(2) of 0.48) with maximum viral load reduction and led to a corresponding 50% effective dose (ED(50)) IQ of 42, with a 95% confidence interval (CI) of 0.1 to 148534. In contrast, the LCIQ-maximum VLR relationship fit into a typical sigmoidal curve with an r(2) value of 0.95 and an ED(50) LCIQ of 121, with a 95% CI of 83 to 177. The present study provides a novel human Kp(liver) prediction model, and the LCIQ correlated well with the viral load reductions observed in short-term HCV monotherapy of different DAAs and provides a valuable tool to guide HCV drug discovery.
Asunto(s)
Antivirales/farmacocinética , Hepacivirus/efectos de los fármacos , Hígado/metabolismo , Animales , Células Cultivadas , Digoxina/farmacocinética , Doxorrubicina/farmacocinética , Hepatocitos/virología , Humanos , Imipramina/farmacocinética , Masculino , Ratones , Quinidina/farmacocinética , Ratas , Ratas Sprague-Dawley , Verapamilo/farmacocinéticaRESUMEN
Human papillomaviruses are responsible for multiple human diseases, including cervical cancer caused by multiple high-risk types and genital warts caused by the low-risk types 6 and 11. Based on the research indicating that low-risk HPV could be successfully targeted by inhibitors of viral DNA replication, we carried out several high-throughput screens for inhibitors of DNA replication activities. Two series were identified in screens for inhibitors of the interaction between the viral proteins E1 and E2. The two series were demonstrated to bind to overlapping sites on the transactivation domain of E2, at the E1-binding interface, by a series of biochemical and biophysical experiments. A member of the first series was also cocrystallized with the E2 transactivation domain. For both series, structure-activity investigations are described, which resulted in several hundred fold improvements in activity. The best compounds in each series had low nanomolar activity against the HPV11 E1-E2 interaction, and EC(50) values in cellular DNA replication assays of approximately 1 µM. Binding modes for the two series are compared, and some general conclusions about the discovery of protein-protein interaction inhibitors are drawn from the work described.
Asunto(s)
Carbamatos , Indanos , Papillomaviridae , Piperidinas , Proteínas Virales/antagonistas & inhibidores , Proteínas Virales/química , Antivirales/química , Antivirales/metabolismo , Antivirales/farmacología , Sitios de Unión , Carbamatos/química , Carbamatos/metabolismo , Carbamatos/farmacología , Proteínas de Unión al ADN/antagonistas & inhibidores , Proteínas de Unión al ADN/química , Proteínas de Unión al ADN/metabolismo , Evaluación Preclínica de Medicamentos/métodos , Humanos , Indanos/química , Indanos/metabolismo , Indanos/farmacología , Simulación de Dinámica Molecular , Papillomaviridae/genética , Papillomaviridae/metabolismo , Piperidinas/química , Piperidinas/metabolismo , Piperidinas/farmacología , Unión Proteica/efectos de los fármacos , Conformación Proteica , Proteínas Virales/metabolismoRESUMEN
The present study describes the cross-species absorption, metabolism, distribution and pharmacokinetics of BI 201335, a potent HCV protease inhibitor currently in phase III clinical trials. BI 201335 showed a good Caco-II permeability (8.7 × 10(-6) cm/sec) and in vitro metabolic stability (predicted hepatic clearence (CL(hep)) <19% Q(h) in all species tested). Single dose PK revealed a clearance of 17, 3.0 and 2.6 mL/min/kg in rat, monkey and dog respectively, with a corresponding oral bioavailability of 29.1, 25.5 and 35.6%. Comparative plasma and liver PK profile in rodents showed a high liver Kp in the rat (42-fold), suggesting high target tissue distribution. Simple allometry based on animal PK predicted a human oral CL/F of 168 mL/min, within two-fold of the observed value (118 mL/min) at 240 mg in healthy volunteers. Allometry of volume of distribution generated a low exponent of 0.59, and a much lower predicted Vss/F (5-fold less than observed). Several different approaches of Vss/F prediction were evaluated and compared with the value observed in human. The averaged Vss/F from preclinical animals provides the best estimation of the observed human value (169 L vs. 175 L). Corresponding human "effective" t(1/2) values were also compared. The predicted human t(1/2) based on the CL from allometry with metabolic corrections and the averaged animal Vss represented the best estimation of the clinical data (12.1 vs. 17.2 hr). The present study demonstrated that the good preclinical ADMEPK profile of BI 201335 is consistent with that observed in the clinic. While preclinical data accurately predicted the human CL, the prediction of human Vss seems to be more challenging. The averaged Vss/F from all tested preclinical animals provided the best prediction of human Vss and the resulting "effective" t(1/2).
Asunto(s)
Antivirales/farmacocinética , Oligopéptidos/farmacocinética , Inhibidores de Proteasas/farmacocinética , Tiazoles/farmacocinética , Proteínas no Estructurales Virales/antagonistas & inhibidores , Absorción , Ácidos Aminoisobutíricos , Animales , Disponibilidad Biológica , Células CACO-2 , Perros , Evaluación Preclínica de Medicamentos , Hepacivirus/enzimología , Humanos , Leucina/análogos & derivados , Macaca mulatta , Masculino , Microsomas Hepáticos , Oligopéptidos/química , Prolina/análogos & derivados , Quinolinas , Ratas , Ratas Sprague-Dawley , Tiazoles/química , Distribución TisularRESUMEN
BACKGROUND & AIMS: BI201335 is a highly specific and potent HCV protease inhibitor. This multiple rising dose trial evaluated antiviral activity and safety in chronic HCV genotype-1 patients. METHODS: Thirty-four treatment-naïve patients were randomized to monotherapy with placebo or BI201335 at 20-240 mg once-daily for 14 days, followed by combination with pegylated interferon alfa/ribavirin (PegIFN/RBV) through Day 28. Nineteen treatment-experienced patients received 48-240 mg BI201335 once-daily with PegIFN/RBV for 28 days. HCV-RNA was measured with Roche COBAS TaqMan. RESULTS: In treatment-naïve patients, median maximal viral load (VL) reductions during 14-day monotherapy were -3.0, -3.6, -3.7, and -4.2 log(10) for the 20, 48, 120, and 240 mg groups. VL breakthroughs (≥1 log(10) from nadir) were seen in most patients on monotherapy and were caused by NS3/4A variants (R155K, D168V) conferring in vitro resistance to BI201335. Adding PegIFN/RBV at Days 15-28 led to continuous viral load reductions in most patients. In treatment-experienced patients, treatment with BI201335 and PegIFN/RBV achieved VL<25 IU/ml at Day 28 in 3/6, 4/7, and 5/6 patients in the 48, 120, and 240 mg dose groups. VL breakthroughs were observed during triple combination in only 3/19 patients. BI201335 was generally well tolerated. Mild rash or photosensitivity was detected in four patients. Mild unconjugated hyperbilirubinemia was the only dose-dependent laboratory abnormality of BI201335. BI201335 elimination half-life supports once-daily dosing. CONCLUSIONS: BI201335 combined with PegIFN/RBV was well tolerated and induced strong antiviral responses. These results support further development of BI201335 in HCV genotype-1 patients.
Asunto(s)
Antivirales/farmacología , Hepatitis C/tratamiento farmacológico , Oligopéptidos/farmacología , Inhibidores de Proteasas/farmacología , Tiazoles/farmacología , Adulto , Ácidos Aminoisobutíricos , Antivirales/administración & dosificación , Antivirales/efectos adversos , Antivirales/farmacocinética , Proteínas Portadoras/antagonistas & inhibidores , Método Doble Ciego , Farmacorresistencia Viral/genética , Femenino , Hepacivirus/efectos de los fármacos , Hepacivirus/enzimología , Hepacivirus/genética , Hepatitis C/sangre , Hepatitis C/virología , Humanos , Interferón alfa-2 , Interferón-alfa/administración & dosificación , Péptidos y Proteínas de Señalización Intracelular , Leucina/análogos & derivados , Masculino , Persona de Mediana Edad , Oligopéptidos/administración & dosificación , Oligopéptidos/efectos adversos , Oligopéptidos/farmacocinética , Polietilenglicoles/administración & dosificación , Prolina/análogos & derivados , Inhibidores de Proteasas/administración & dosificación , Inhibidores de Proteasas/efectos adversos , Inhibidores de Proteasas/farmacocinética , Quinolinas , Proteínas Recombinantes , Ribavirina/administración & dosificación , Tiazoles/administración & dosificación , Tiazoles/efectos adversos , Tiazoles/farmacocinética , Carga Viral/efectos de los fármacos , Proteínas no Estructurales Virales/antagonistas & inhibidores , Proteínas no Estructurales Virales/genéticaRESUMEN
BI 201335 is a hepatitis C virus (HCV) NS3-NS4A (NS3 coexpressed with NS4A) protease inhibitor that has been shown to have potent clinical antiviral activity. It is a highly optimized noncovalent competitive inhibitor of full-length NS3-NS4A proteases of HCV genotypes 1a and 1b with K(i) values of 2.6 and 2.0 nM, respectively. K(i) values of 2 to 230 nM were measured against the NS3-NS4A proteases of HCV genotypes 2 to 6, whereas it was a very weak inhibitor of cathepsin B and showed no measurable inhibition of human leukocyte elastase. BI 201335 was also shown to be a potent inhibitor of HCV RNA replication in vitro with 50% effective concentrations (EC(50)s) of 6.5 and 3.1 nM obtained in genotype 1a and 1b replicon assays. Combinations of BI 201335 with either interferon or ribavirin had additive effects in replicon assays. BI 201335 had good permeability in Caco-2 cell assays and high metabolic stability after incubation with human, rat, monkey, and dog liver microsomes. Its good absorption, distribution, metabolism, and excretion (ADME) profile in vitro, as well as in rat, monkey, and dog, predicted good pharmacokinetics (PK) in humans. Furthermore, drug levels were significantly higher in rat liver than in plasma, suggesting that distribution to the target organ may be especially favorable. BI 201335 is a highly potent and selective NS3-NS4A protease inhibitor with good in vitro and animal ADME properties, consistent with its good human PK profile, and shows great promise as a treatment for HCV infection.
Asunto(s)
Proteínas Portadoras/antagonistas & inhibidores , Hepacivirus/enzimología , Oligopéptidos/farmacología , Oligopéptidos/farmacocinética , Tiazoles/farmacología , Tiazoles/farmacocinética , Proteínas no Estructurales Virales/antagonistas & inhibidores , Proteínas Virales/antagonistas & inhibidores , Ácidos Aminoisobutíricos , Animales , Antivirales/farmacocinética , Antivirales/farmacología , Células CACO-2 , Línea Celular Tumoral , Humanos , Péptidos y Proteínas de Señalización Intracelular , Leucina/análogos & derivados , Masculino , Prolina/análogos & derivados , Prolina/farmacología , Inhibidores de Proteasas/farmacocinética , Inhibidores de Proteasas/farmacología , Quinolinas , Ratas , Proteínas no Estructurales Virales/efectos de los fármacos , Replicación Viral/efectos de los fármacosRESUMEN
The bifunctional NS3 protease-helicase of hepatitis C virus (HCV), together with its cofactor protein NS4A, is an important target for antiviral drugs which can cure HCV infections. HCV strains are divided into six major genotypes based on sequence diversity, and the great majority of reports on NS3 have focused exclusively on genotype 1 proteins. Here we report the cloning, expression, and preliminary characterization of NS3-NS4A gene products from HCV genotypes 4, 5, and 6. This work complements our earlier characterization of genotype 2 and 3 proteins [17]. We compare NS3-NS4A protease and helicase activities of genotypes 4a, 5a, and 6a to those of common reference strains Con1 (genotype 1b) and JFH1 (genotype 2a). The specific activities of the proteases of the newly isolated proteins were similar to those of the reference proteins. Furthermore, the reference inhibitor BILN 2061 had similar activity against all of the proteins except for that of JFH1, which had an apparent K(i) that was 11-fold higher relative to Con1. RNA and DNA unwinding activities were also similar for genotypes 1, 4, 5, and 6 proteins, but significantly higher for genotype 2 JFH1. With the availability of these proteins, inhibitors developed based on their activity against genotype 1 can be tested against all the other major genotypes, providing a path to improved treatment for all HCV patients.
Asunto(s)
Proteínas Portadoras/metabolismo , Hepacivirus/enzimología , ARN Helicasas/metabolismo , Proteínas no Estructurales Virales/metabolismo , Proteínas Virales/metabolismo , Secuencia de Aminoácidos , Antivirales/química , Antivirales/farmacología , Carbamatos/farmacología , Proteínas Portadoras/antagonistas & inhibidores , Proteínas Portadoras/genética , Clonación Molecular , ADN/metabolismo , Genotipo , Hepacivirus/genética , Hepacivirus/aislamiento & purificación , Humanos , Péptidos y Proteínas de Señalización Intracelular , Compuestos Macrocíclicos/farmacología , Datos de Secuencia Molecular , Inhibidores de Proteasas/química , Inhibidores de Proteasas/farmacología , Quinolinas/farmacología , ARN/metabolismo , ARN Helicasas/antagonistas & inhibidores , ARN Helicasas/genética , Tiazoles/farmacología , Proteínas no Estructurales Virales/antagonistas & inhibidores , Proteínas no Estructurales Virales/genética , Proteínas Virales/antagonistas & inhibidores , Proteínas Virales/genéticaRESUMEN
Thermodynamic parameters were determined for structurally-related inhibitors of HCV NS3 protease to assess how binding entropies and enthalpies vary with incremental changes at the P2 and P3 inhibitor subsites. Changing the heterocyclic substituent at P2 from a pyridyl to a 7-methoxy-2-phenyl-4-quinolyl group leads to a 710-fold increase in affinity. Annelating a benzene ring onto a pyridine ring leads to quinoline-derived inhibitors having higher affinities, but the individual enthalpy and entropy contributions are markedly different for each ligand pair. Introducing a phenyl group at C2 of the heterocyclic ring at P2 uniformly leads to higher affinity analogs with more favorable binding entropies, while adding a methoxy group at C7 of the quinoline ring at P2 provides derivatives with more favorable binding enthalpies. Significant enthalpy/entropy compensation is observed for structural changes made to inhibitors lacking a 2-phenyl substituent, whereas favorable changes in both binding enthalpies and entropies accompany structural modifications when a 2-phenyl group is present. Overall, binding energetics of inhibitors having a 2-phenyl-4-quinolyl group at P2 are dominated by entropic effects, whereas binding of the corresponding norphenyl analogs are primarily enthalpy driven. Notably, the reversal from an entropy driven association to an enthalpy driven one for this set of inhibitors also correlates with alternate binding modes. When the steric bulk of the side chain at P3 is increased from a hydrogen atom to a tert-butyl group, there is a 770-fold improvement in affinity. The 30-fold increase resulting from the first methyl group is solely the consequence of a more favorable change in entropy, whereas subsequent additions of methyl groups leads to modest increases in affinity that arise primarily from incremental improvements in binding enthalpies accompanied with smaller favorable entropic contributions.
Asunto(s)
Oligopéptidos/farmacología , Inhibidores de Proteasas/farmacología , Termodinámica , Proteínas no Estructurales Virales/antagonistas & inhibidores , Relación Dosis-Respuesta a Droga , Ligandos , Estructura Molecular , Oligopéptidos/química , Inhibidores de Proteasas/química , Relación Estructura-Actividad , Proteínas no Estructurales Virales/metabolismoRESUMEN
The NS3 protein of hepatitis C virus is unusual because it encodes two unrelated enzymatic activities in linked protease and helicase domains. It has also been intensively studied because inhibitors targeting its protease domain have potential to significantly improve treatment options for those infected with this virus. Many enzymological studies and inhibitor discovery programs have been carried out using the isolated protease domain in complex with a peptide derived from NS4A which stimulates activity. However, some recent publications have suggested that the NS3 helicase domain may influence inhibitor binding and thus suggest work should focus on the full-length NS3-NS4A protein. Here we present the characterization of a single-chain protease in which the NS4A peptide activator is linked to the N-terminus of the NS3 protease domain. This protein behaves well in solution, and its protease activity is very similar to that of full-length NS3-NS4A. We find that this fusion protein, as well as the noncovalent complex of the NS4A peptide with NS3, gives similar Ki values, spanning 3 orders of magnitude, for a set of 25 structurally diverse inhibitors. We also show that simultaneous mutation of three residues on the surface of the helicase domain which has been hypothesized to interact with the protease does not significantly affect enzymatic activity or inhibitor binding. Thus, the protease domain with the NS4A peptide, in a covalent or noncovalent complex, is a good model for the protease activity of native NS3-NS4A.
Asunto(s)
Proteínas Portadoras/genética , Proteínas Portadoras/metabolismo , Hepacivirus/metabolismo , Inhibidores de Proteasas/metabolismo , ARN Helicasas/metabolismo , Proteínas no Estructurales Virales/metabolismo , Proteínas Virales/genética , Proteínas Virales/metabolismo , Secuencia de Aminoácidos , Proteínas Portadoras/química , Cristalografía por Rayos X , Dimerización , Activación Enzimática/genética , Hepacivirus/química , Hepacivirus/genética , Péptidos y Proteínas de Señalización Intracelular , Modelos Moleculares , Datos de Secuencia Molecular , Inhibidores de Proteasas/química , Unión Proteica/genética , Estructura Terciaria de Proteína/genética , ARN Helicasas/química , ARN Helicasas/genética , Proteínas Recombinantes de Fusión/química , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/metabolismo , Serina Endopeptidasas/química , Serina Endopeptidasas/genética , Serina Endopeptidasas/metabolismo , Proteínas no Estructurales Virales/química , Proteínas no Estructurales Virales/genética , Proteínas Virales/químicaRESUMEN
Prone positioning affords significant benefits for the fixation of trimalleolar ankle fractures and has been the long-time standard for treatment of these injuries. However, 2 primary disadvantages hamper its utility. First, access to the medial ankle is impeded by the contralateral limb and inability to rotate the operative leg to the extent that is possible in other positions. Second, lateral fluoroscopic imaging of the ankle can be cumbersome and often necessitates physically elevating the ankle for a radiograph then placing it back on the operative table. We describe a simple and cost-conscious technique for overcoming these obstacles of prone positioning in ankle fracture surgery. Judicious placement of a radiolucent triangle under the nonoperative leg in the prone position allows for unobstructed access to the medial ankle in conjunction with simplified lateral fluoroscopic imaging. An alternative technique is to place the radiolucent triangle under the operative leg with the bed in reverse Trendelenberg. Surgeons should consider adding these positioning techniques to their operative armamentarium for usage in appropriate cases. LEVELS OF EVIDENCE: Level V.
Asunto(s)
Fracturas de Tobillo/diagnóstico por imagen , Fracturas de Tobillo/cirugía , Cuidados Intraoperatorios/instrumentación , Posicionamiento del Paciente , Posición Prona , Articulación del Tobillo/diagnóstico por imagen , Articulación del Tobillo/cirugía , Fluoroscopía , HumanosRESUMEN
The Boehringer Ingelheim compound collection was screened for inhibitors of the ATPase activity of human papillomavirus E1 helicase to develop antiviral agents that inhibit human papillomavirus (HPV) DNA replication. This screen led to the discovery of (biphenyl-4-sulfonyl)acetic acid 1, which inhibits the ATPase activity of HPV type 6 E1 helicase with a low micromolar IC(50) value. A hit-to-lead exercise rapidly converted 1 into a low nanomolar lead series.
Asunto(s)
Acetatos/síntesis química , Adenosina Trifosfatasas/antagonistas & inhibidores , Compuestos de Bifenilo/síntesis química , Proteínas Oncogénicas Virales/antagonistas & inhibidores , Papillomaviridae/enzimología , Sulfonas/síntesis química , Acetatos/química , Adenosina Trifosfatasas/química , Antivirales/síntesis química , Antivirales/química , Compuestos de Bifenilo/química , Humanos , Proteínas Oncogénicas Virales/química , Relación Estructura-Actividad , Sulfonas/químicaRESUMEN
As an obligate step for picornaviruses to replicate their genome, the small viral peptide VPg must first be specifically conjugated with uridine nucleotides at a conserved tyrosine hydroxyl group. The resulting VPg-pUpU serves as the primer for genome replication. The uridylylation reaction requires the coordinated activity of many components, including the viral polymerase, a conserved internal RNA stem loop structure, and additional viral proteins. Formation of this complex and the resulting conjugation reaction catalyzed by the polymerase, offers a number of biochemical targets for inhibition of an essential process in the viral life cycle. Therefore, an assay recapitulating uridylylation would provide multiple opportunities for discovering potential antiviral agents. Our goal was to identify inhibitors of human rhinovirus (HRV) VPg uridylylation, which might ultimately be useful to reduce or prevent HRV-induced lower airway immunologic inflammatory responses, a major cause of asthma and chronic obstructive pulmonary disease exacerbations. We have reconstituted the complex uridylylation reaction in an AlphaScreen suitable for high-throughput screening, in which a rabbit polyclonal antiserum specific for uridylylated VPg serves as a key reagent. Assay results were validated by quantitative mass spectrometric detection of uridylylation.
Asunto(s)
Ensayos Analíticos de Alto Rendimiento , Oligorribonucleótidos/genética , Uridina/genética , Genoma Viral , Humanos , Oligorribonucleótidos/antagonistas & inhibidores , ARN Viral/genética , Tirosina/genética , Uridina/antagonistas & inhibidores , Replicación ViralRESUMEN
Given the emergence of resistance observed for the current clinical-stage hepatitis C virus (HCV) NS3 protease inhibitors, there is a need for new inhibitors with a higher barrier to resistance. We recently reported our rational approach to the discovery of macrocyclic acylsulfonamides as HCV protease inhibitors addressing potency against clinically relevant resistant variants. Using X-ray crystallography of HCV protease variant/inhibitor complexes, we shed light on the complex structural mechanisms by which the D168V and R155K residue mutations confer resistance to NS3 protease inhibitors. Here, we disclose SAR investigation and ADME/PK optimization leading to the identification of inhibitors with significantly improved potency against the key resistant variants and with increased liver partitioning.